FACT SHEET: TRANSMEDICS™
_____________________________________________________________________________
Overview
Headquartered in Andover, Massachusetts, TransMedics™ is a privately held medical device company founded in 1998 to address the unmet need for better, more effective organ transplant technologies. The Company has developed the first and only system that allows a new type of organ transplant, called a living organ transplant. This breakthrough, investigational technology, called an Organ Care System, is designed to maintain organs in a warm functioning state outside of the body during transport from organ donor to recipient. The goal of TransMedics’ technology is to improve outcomes and increase organ availability for the growing population of patients with end-stage organ failure in need of a transplant, bridging the ever-widening gap between the number of organs and the number of recipients awaiting transplants. For more information visit www.TransMedics.com.
Mission
TransMedics’ mission is to enable more patients with end-stage organ failure to benefit from the accepted medical standard of care—successful transplantation. The TransMedics Organ Care System is designed to help to improve the health of organs being transplanted as well as increase the number of organs available, improving outcomes, and reducing recovery time, hospital stays and reliance on ongoing medical therapies.
A New Category of Medical Device: The Organ Care System
Despite dramatic medical advances in the science of organ transplant, one key area has remained virtually unchanged for decades – the way that organs are preserved and transported from donor to recipient. To date, organs are removed from a donor and literally placed on ice in a cold, non-functioning state. This method creates severe time limitations while potentially causing injury to the organ and significant underutilization of the current pool of consented, donated organs. TransMedics’ patented technology, the Organ Care System, maintains organs in a functioning state outside the body, pumping warm, oxygenated, nutrient-rich blood through the organ. The system is designed to help meet the need for healthy organs for transplant by potentially improving the health of the organ, allowing more time between donation and transplant, increasing the distance an organ can travel, and allowing surgeons the opportunity to asses the organ before transplant for better overall outcomes. The Organ Care System enters clinical trials in Europe during the first quarter of 2006. It is not yet approved for clinical use in Europe or the United States.
Executive Committee
With more than 150 years of combined experience, the TransMedics executive team has deep knowledge and experience in medical devices and technology. Members of the executive team include: Waleed Hassanein, MD – President & Tamer Khayal, MD – Director, Clinical CEO Development Jim Rao – Vice President, Finance Pam Goldstein – Director, Quality David Kolstad – Vice President, Assurance Marketing Anabella Jucius – Director, Clinical Kypp Morrow – Vice President, Europe Affairs/Trials Robert Young – Vice President, Jon Trachtenberg, Esq. – Director, IP & Manufacturing Operations In-house Counsel Christine Brauer, PhD – Vice President of Regulatory Affairs (Acting)
Scientific Advisors
Valluvan Jeevanandam, MD – Chief Section of Cardiothoracic Surgery, Professor of Surgery, University of Chicago (Chicago, IL) Robert L. Kormos, MD – Co-Director Heart Transplantation, Director Artificial Heart Program, UPMC (Pittsburgh, PA); Medical Director, McGowan Institute for Regenerative Medicine (Pittsburgh, PA) José Núñez, MD, PhD – Professor of Surgery, Complutensis University of Madrid (Madrid, Spain); Transplant Coordinator and Tissue Bank Director, Hospital Clínico “San Carlos” (Madrid, Spain) Bruce Rosengard, MD, FRCS, FACS – British Heart Foundation Professor and Chair of Cardiothoracic Surgery, University of Cambridge at Papworth Hospital (Papworth, UK) Ryszard T. Smolenski, MD, PhD – Head of Metabolic Research, Heart Science Centre, Imperial College at Harefield Hospital (Harefield, UK) Scott Solomon, MD – Director of Non-Invasive Cardiology, Brigham and Women’s Hospital, Associate Professor of Medicine, Harvard Medical School (Boston, MA) Gayle Winters, MD – Cardiac Pathologist, Director, Autopsy Division, Brigham and Women’s Hospital (Boston, MA)
Investors
To date, TransMedics has raised $35 million in venture capital funding, including investments from the following firms: 3i Group Novel Bioventure Alta Partners Posco BioVentures CB Health Ventures Sherbrooke Capital Flagship Ventures VantagePoint Venture Partners JP Morgan
Contact Information
David Kolstad, dkolstad@transmedics.com (978) 552-1905 Maria Favorito, mfavorito@webershandwick.com (617) 520-7266